Nabriva Therapeutics, an Austrian biotechnology company focused on developing a new class of antibiotics called pleuromutilins for the treatment of serious infections caused by resistant gram-positive and gram-negative pathogens, has appointed Colin Broom as Chief Executive.
Current CEO Ralf Schmid will remain a member of the executive management team and move to the role of Chief Operating Officer (COO) and Chief Financial Officer (CFO).
The company has also established a US subsidiary, based in Philadelphia, Pennsylvania, where the clinical development team will be located. All other activities will remain in Vienna.
Nabriva plans to take its lead product lefamulin (BC-3781) into late stage development in community-acquired bacterial pneumonia and advance its pipeline of Extended Spectrum Pleuromutilins (ESP), active against gram-negative bacteria.
Broom has worked in biopharmaceutical drug development and commercialisation for 30 years. Most recently he was Chief Scientific Officer at ViroPharma, which was acquired by Shire for US$4.2bn in January. Prior development roles included senior positions at Amgen, Hoechst Marion Roussel (now Sanofi), SmithKline Beecham and Glaxo (now GlaxoSmithKline). Broom also serves on the board of NPS Pharmaceuticals.
